EU Drug Regulation Reform – Why pharmacovigilance matters more than ever

The reform of EU pharmaceutical legislation marks a new era in how medicinal products are regulated, monitored, and made available to patients across the European Union. As outlined by the European Medicines Agency (EMA), this is the most significant update of EU pharmaceutical rules in more than 20 years, aiming to modernise regulatory processes, strengthen supply security, and ensure faster access to safe and effective medicines while maintaining the highest standards of public health protection.

At the core of this evolving framework lies pharmacovigilance — the science and activities related to detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. Why pharmacovigilance matters has never been clearer: once a medicine enters the market, real-world data becomes essential for continuous benefit–risk evaluation and for maintaining patient trust.

A cornerstone of the EU pharmacovigilance system is EudraVigilance, the centralised database that enables the electronic submission and analysis of safety data, including every adverse drug reaction report received from healthcare professionals, patients, and marketing authorisation holders. Through structured signal detection, regulators and companies can identify emerging safety concerns early and take appropriate regulatory action in line with Good Pharmacovigilance Practices (GVP).

Pharmacovigilance under the new EU pharmaceutical legislation

The EU Drug Regulation Reform places strong emphasis on simplification, digitalisation, and lifecycle-based regulation. New and updated PV requirements will increasingly rely on digital tools, harmonised data standards, and proactive risk management approaches. EMA and EU Member States are expected to issue implementation guidance to support companies in adapting their pharmacovigilance systems to the revised legal framework.

Central to compliance remains the Pharmacovigilance System Master File (PSMF), which documents how a company fulfils its pharmacovigilance obligations, supported by robust governance, qualified personnel, and effective processes. A well-designed pharmacovigilance risk management plan ensures that identified and potential risks are appropriately monitored and mitigated throughout a product’s lifecycle.

The growing role of pharmacovigilance outsourcing

As regulatory expectations increase, many companies are turning to pharmacovigilance outsourcing to manage complexity efficiently. Selecting a reliable pharmacovigilance vendor allows organisations to access specialised expertise, scalable resources, and validated pharmacovigilance software solutions that support case management, signal detection, and regulatory reporting in line with EU standards.

Regular pharmacovigilance audits are also critical to ensure system compliance, inspection readiness, and continuous improvement — particularly in light of upcoming legislative changes.

Billev Pharma East – Supporting compliance in a changing regulatory landscape

Based in Ljubljana, Slovenia, Billev Pharma East plays a key role in supporting life sciences companies navigating the EU Drug Regulation Reform. As a specialised regulatory and pharmacovigilance consultancy, the company provides end-to-end support for building, maintaining, and optimising compliant pharmacovigilance systems.

Our services include adverse event management, preparation and maintenance of the PSMF, structured signal detection, benefit–risk evaluation, and tailored risk management planning. Billev Pharma East also offers Qualified Person for Pharmacovigilance (QPPV) services with 24/7 medical support, as well as readiness assessments and support during inspections and audits.

Beyond pharmacovigilance, the company delivers integrated Regulatory Affairs services covering early development strategy, regulatory submissions, lifecycle management, and alignment with digital regulatory requirements introduced under the EU reform. This integrated approach ensures that regulatory strategy and safety oversight evolve together.

Investing in expertise and people

As the regulatory environment becomes more sophisticated, so does the demand for qualified professionals. A career in pharmacovigilance continues to grow in importance, with roles such as pharmacovigilance manager playing a central role in ensuring compliance, patient safety, and regulatory excellence across organisations.

The EU pharmaceutical legislation reform underscores the strategic importance of pharmacovigilance as a pillar of patient safety and regulatory compliance. Companies that proactively invest in robust systems, expert partners, and forward-looking regulatory strategies will be best positioned to meet new expectations and thrive in a competitive European market.

With deep expertise across pharmacovigilance, regulatory affairs, quality systems, and digital solutions, Billev Pharma East stands out as a trusted partner for organisations seeking to adapt to the reformed EU regulatory framework and maintain best-in-class safety practices across their product portfolios.

Meet Our Team

At Billev Pharma East, our contribution to the international scientific and regulatory community includes speaking engagements by members of our team at key conferences in 2026. These events focus on preventive medicine, public health, pharmacovigilance, drug safety, and related regulatory topics:

• 6th International Conference on the Future of Preventive Medicine and Public Health
  23–24 March 2026 | Rome, Italy
• DIA Europe 2026
  24–26 March 2026 | Rotterdam, Netherlands
• Public Safety and Global Health Congress
  27–28 April 2026 | Singapore
• ICPDS 2026 – 20th International Conference on Pharmacovigilance and Drug Safety
  18–19 May 2026 | London, United Kingdom